Indian Pharmacopoeia Commission
Autonomous institution under India's Ministry of Health and Family Welfare; publishes the Indian Pharmacopoeia, the legally enforceable book of drug standards under the Drugs and Cosmetics Act, 1940, and runs the Pharmacovigilance Programme of India.
What this page does not claim
SPEQ curates and cross-references these bodies. It is not affiliated with, accredited by, or endorsed by any of them, and a count of decoded standards is a measure of SPEQ’s coverage, not of a body’s importance.
WHAT IPC COVERS
The Indian Pharmacopoeia Commission (IPC) is an autonomous institution under India's Ministry of Health and Family Welfare, established in 2005 and fully operational from 1 January 2009. Its central mandate is to publish the Indian Pharmacopoeia (IP) — the official book of standards for drugs manufactured and marketed in India — which is legally enforceable under the Drugs and Cosmetics Act, 1940. The IP sets the identity, purity, strength, quality, and safety standards a drug must meet, through general chapters (test methods and apparatus) and monographs for active ingredients, excipients, dosage forms, vaccines and immunosera, biotechnology-derived products, and blood products. The current edition is IP 2026, the 10th Edition, released on 2 January 2026 with 121 new monographs, bringing the total to about 3,340 official standards. Beyond the compendium, IPC supplies IP Reference Substances for the official methods and is the National Coordination Centre for the Pharmacovigilance Programme of India (PvPI).
WHAT IPC PUBLISHES
- 01The Indian Pharmacopoeia — the official book of drug standards (current: IP 2026, 10th Edition, 2 January 2026)
- 02Addenda and supplements that update the current edition between full revisions
- 03IP Reference Substances (IPRS) used to run the official compendial methods
- 04National Formulary of India and Pharmacovigilance Programme of India (PvPI) outputs
HOW ITS REQUIREMENTS BITE
Reference, not inspection. The IP acquires legal force by reference: under the Drugs and Cosmetics Act, 1940, a drug for the Indian market that is the subject of an IP monograph must comply with that monograph's standard, so the compendium is the specification against which quality is judged rather than a body that licenses or inspects. IPC compiles and publishes the standards and issues addenda between editions; the Central Drugs Standard Control Organisation (CDSCO) and the State drug regulators are the authorities that enforce them through licensing, testing, and inspection. The distinction matters: IPC sets the public quality standard, the drug regulators apply it.
What practitioners get wrong
- Compliance is per-monograph: where an IP monograph exists for a product, meeting it is a condition of the Indian market — verify the monograph and the current addendum state, not just the edition on the shelf.
- Attribute correctly: IPC sets the standard; CDSCO and the State regulators enforce it. Dossiers that treat "IP" and "CDSCO" as one body invert the hierarchy.
- The IP is a national compendium with its own monographs and acceptance criteria; do not assume a USP, BP, or Ph. Eur. monograph is interchangeable with the IP standard for the Indian market.
- IPC also runs PvPI, so the same body carries both the compendial-standards and the national-pharmacovigilance mandates — a breadth that is easy to miss.
WHERE IT SITS INTERNATIONALLY
The Indian Pharmacopoeia sits alongside the other national and regional compendia — the Japanese Pharmacopoeia, the British Pharmacopoeia, the Chinese Pharmacopoeia, and the United States Pharmacopeia — and the WHO International Pharmacopoeia, each legally operative in its own territory. India participates in the wider ICH framework, and IPC engages in pharmacopoeial harmonisation discussions, but an IP monograph remains the standard that governs the Indian market and is not automatically satisfied by compliance with a foreign compendium.
IPC STANDARDS SPEQ DECODES · 1
DISCIPLINES IN IPC’S REMIT
IPC: frequently asked questions
Reference answers on Indian Pharmacopoeia Commission’s mandate, what it publishes, and how its requirements acquire force.
What is the current edition of the Indian Pharmacopoeia?
IP 2026, the 10th Edition, released on 2 January 2026. It added 121 new monographs, bringing the total to about 3,340 official drug standards, and is updated between editions by addenda.
Is the Indian Pharmacopoeia legally binding?
Yes. The IP is the official book of standards under the Drugs and Cosmetics Act, 1940: a drug marketed in India that is the subject of an IP monograph must comply with that monograph.
Who publishes the Indian Pharmacopoeia, and who enforces it?
The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health and Family Welfare, compiles and publishes it; CDSCO and the State drug regulators enforce it through licensing, testing, and inspection.